Table 3.
Open in new tab

Factors Predictive of HBsAg Loss for the 360 Propensity Score-Matched Patients

VariableComparisonUnivariate AnalysisMultivariate Analysis
HR (95% CI)P valueHR (95% CI)P value
Start entecavir treatment
AgeIncrease per y1.03 (0.98–1.08).22
SexMale vs female0.77 (0.30–1.98).59
ALTIncrease per U/L1.000 (0.999–1.001).82
ALT, U/L<2×, 2-5 ×, and >5 × ULN0.94 (0.55–1.63).83
Total bilirubinIncrease per mg/dL1.01 (0.81–1.26).93
Prior interferon useYes vs no0.28 (0.04–2.08).21
HBV DNA at baselineIncrease per 1 unit0.68 (0.50–0.92).012
HBV genotype, C vs BC vs B0.90 (0.30–2.69).85
PlateletIncrease per 103/μL1.000 (0.992–1.009).92
FIB-4 indexIncrease per 1 unit1.01 (0.90–1.14).83
HBsAg at baselineIncrease per log10 IU/mL0.26 (0.15–0.46)<.001
HBsAg at 12 mo of treatmentIncrease per log10 IU/mL0.18 (0.09–0.36)<.001
GroupsDiscontinued vs continued4.53 (1.52–13.56).0075.27 (1.72–16.14).004
End of treatment (discontinued group) or 3 y of treatment (continued group)
Age, per yIncrease per y1.03 (0.99–1.08).19
ALT, U/LIncrease per U/L0.97 (0.92–1.01).14
Total bilirubin, mg/dLIncrease per mg/dL0.38 (0.07–1.92).24
FIB-4 index, per 1 unitIncrease per 1 unit1.17 (0.72–1.92).53
HBsAg, per log10 IU/mLIncrease per log10 IU/mL0.12 (0.06–0.23)<.0010.11 (0.05–0.21)<.001
HBsAg, <150 vs ≥150 IU/mLYes vs no14.04 (5.06–38.97)<.001
HBsAg decline from baselineIncrease per log10 IU/mL1.32 (0.66–2.46).47
Consolidation duration, per wkIncrease per wk1.012 (1.001–1.022).025
≥78 vs <78 wk0.84 (0.11–6.56).87
≥104 vs <104 wk0.81 (0.23–2.87).75
≥130 vs <130 wk0.82 (0.33–2.04).66
VariableComparisonUnivariate AnalysisMultivariate Analysis
HR (95% CI)P valueHR (95% CI)P value
Start entecavir treatment
AgeIncrease per y1.03 (0.98–1.08).22
SexMale vs female0.77 (0.30–1.98).59
ALTIncrease per U/L1.000 (0.999–1.001).82
ALT, U/L<2×, 2-5 ×, and >5 × ULN0.94 (0.55–1.63).83
Total bilirubinIncrease per mg/dL1.01 (0.81–1.26).93
Prior interferon useYes vs no0.28 (0.04–2.08).21
HBV DNA at baselineIncrease per 1 unit0.68 (0.50–0.92).012
HBV genotype, C vs BC vs B0.90 (0.30–2.69).85
PlateletIncrease per 103/μL1.000 (0.992–1.009).92
FIB-4 indexIncrease per 1 unit1.01 (0.90–1.14).83
HBsAg at baselineIncrease per log10 IU/mL0.26 (0.15–0.46)<.001
HBsAg at 12 mo of treatmentIncrease per log10 IU/mL0.18 (0.09–0.36)<.001
GroupsDiscontinued vs continued4.53 (1.52–13.56).0075.27 (1.72–16.14).004
End of treatment (discontinued group) or 3 y of treatment (continued group)
Age, per yIncrease per y1.03 (0.99–1.08).19
ALT, U/LIncrease per U/L0.97 (0.92–1.01).14
Total bilirubin, mg/dLIncrease per mg/dL0.38 (0.07–1.92).24
FIB-4 index, per 1 unitIncrease per 1 unit1.17 (0.72–1.92).53
HBsAg, per log10 IU/mLIncrease per log10 IU/mL0.12 (0.06–0.23)<.0010.11 (0.05–0.21)<.001
HBsAg, <150 vs ≥150 IU/mLYes vs no14.04 (5.06–38.97)<.001
HBsAg decline from baselineIncrease per log10 IU/mL1.32 (0.66–2.46).47
Consolidation duration, per wkIncrease per wk1.012 (1.001–1.022).025
≥78 vs <78 wk0.84 (0.11–6.56).87
≥104 vs <104 wk0.81 (0.23–2.87).75
≥130 vs <130 wk0.82 (0.33–2.04).66

Abbreviations: ALT, alanine aminotransferase, CI, confidence interval; FIB-4, fibrosis 4; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HR, hazard ratio.

Table 3.
Open in new tab

Factors Predictive of HBsAg Loss for the 360 Propensity Score-Matched Patients

VariableComparisonUnivariate AnalysisMultivariate Analysis
HR (95% CI)P valueHR (95% CI)P value
Start entecavir treatment
AgeIncrease per y1.03 (0.98–1.08).22
SexMale vs female0.77 (0.30–1.98).59
ALTIncrease per U/L1.000 (0.999–1.001).82
ALT, U/L<2×, 2-5 ×, and >5 × ULN0.94 (0.55–1.63).83
Total bilirubinIncrease per mg/dL1.01 (0.81–1.26).93
Prior interferon useYes vs no0.28 (0.04–2.08).21
HBV DNA at baselineIncrease per 1 unit0.68 (0.50–0.92).012
HBV genotype, C vs BC vs B0.90 (0.30–2.69).85
PlateletIncrease per 103/μL1.000 (0.992–1.009).92
FIB-4 indexIncrease per 1 unit1.01 (0.90–1.14).83
HBsAg at baselineIncrease per log10 IU/mL0.26 (0.15–0.46)<.001
HBsAg at 12 mo of treatmentIncrease per log10 IU/mL0.18 (0.09–0.36)<.001
GroupsDiscontinued vs continued4.53 (1.52–13.56).0075.27 (1.72–16.14).004
End of treatment (discontinued group) or 3 y of treatment (continued group)
Age, per yIncrease per y1.03 (0.99–1.08).19
ALT, U/LIncrease per U/L0.97 (0.92–1.01).14
Total bilirubin, mg/dLIncrease per mg/dL0.38 (0.07–1.92).24
FIB-4 index, per 1 unitIncrease per 1 unit1.17 (0.72–1.92).53
HBsAg, per log10 IU/mLIncrease per log10 IU/mL0.12 (0.06–0.23)<.0010.11 (0.05–0.21)<.001
HBsAg, <150 vs ≥150 IU/mLYes vs no14.04 (5.06–38.97)<.001
HBsAg decline from baselineIncrease per log10 IU/mL1.32 (0.66–2.46).47
Consolidation duration, per wkIncrease per wk1.012 (1.001–1.022).025
≥78 vs <78 wk0.84 (0.11–6.56).87
≥104 vs <104 wk0.81 (0.23–2.87).75
≥130 vs <130 wk0.82 (0.33–2.04).66
VariableComparisonUnivariate AnalysisMultivariate Analysis
HR (95% CI)P valueHR (95% CI)P value
Start entecavir treatment
AgeIncrease per y1.03 (0.98–1.08).22
SexMale vs female0.77 (0.30–1.98).59
ALTIncrease per U/L1.000 (0.999–1.001).82
ALT, U/L<2×, 2-5 ×, and >5 × ULN0.94 (0.55–1.63).83
Total bilirubinIncrease per mg/dL1.01 (0.81–1.26).93
Prior interferon useYes vs no0.28 (0.04–2.08).21
HBV DNA at baselineIncrease per 1 unit0.68 (0.50–0.92).012
HBV genotype, C vs BC vs B0.90 (0.30–2.69).85
PlateletIncrease per 103/μL1.000 (0.992–1.009).92
FIB-4 indexIncrease per 1 unit1.01 (0.90–1.14).83
HBsAg at baselineIncrease per log10 IU/mL0.26 (0.15–0.46)<.001
HBsAg at 12 mo of treatmentIncrease per log10 IU/mL0.18 (0.09–0.36)<.001
GroupsDiscontinued vs continued4.53 (1.52–13.56).0075.27 (1.72–16.14).004
End of treatment (discontinued group) or 3 y of treatment (continued group)
Age, per yIncrease per y1.03 (0.99–1.08).19
ALT, U/LIncrease per U/L0.97 (0.92–1.01).14
Total bilirubin, mg/dLIncrease per mg/dL0.38 (0.07–1.92).24
FIB-4 index, per 1 unitIncrease per 1 unit1.17 (0.72–1.92).53
HBsAg, per log10 IU/mLIncrease per log10 IU/mL0.12 (0.06–0.23)<.0010.11 (0.05–0.21)<.001
HBsAg, <150 vs ≥150 IU/mLYes vs no14.04 (5.06–38.97)<.001
HBsAg decline from baselineIncrease per log10 IU/mL1.32 (0.66–2.46).47
Consolidation duration, per wkIncrease per wk1.012 (1.001–1.022).025
≥78 vs <78 wk0.84 (0.11–6.56).87
≥104 vs <104 wk0.81 (0.23–2.87).75
≥130 vs <130 wk0.82 (0.33–2.04).66

Abbreviations: ALT, alanine aminotransferase, CI, confidence interval; FIB-4, fibrosis 4; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HR, hazard ratio.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close